Audit of principal investigator's compliance for submission of continue review application and decisions taken on lapses in validity of approval by the Institutional Ethics Committee at tertiary oncology center in Navi Mumbai.

Q2 Medicine
Perspectives in Clinical Research Pub Date : 2022-07-01 Epub Date: 2021-02-08 DOI:10.4103/picr.PICR_102_20
Bhavesh Bandekar, Kasturi Awatagiri, Sadhana Kannan, Pallavi Rane, Prafulla Parikh
{"title":"Audit of principal investigator's compliance for submission of continue review application and decisions taken on lapses in validity of approval by the Institutional Ethics Committee at tertiary oncology center in Navi Mumbai.","authors":"Bhavesh Bandekar,&nbsp;Kasturi Awatagiri,&nbsp;Sadhana Kannan,&nbsp;Pallavi Rane,&nbsp;Prafulla Parikh","doi":"10.4103/picr.PICR_102_20","DOIUrl":null,"url":null,"abstract":"<p><strong>Context: </strong>A failure to obtain continued Institutional Ethics Committee (IEC) approval for the study before the expiry date assigned by the IEC is considered as \"lapse of the IEC approval\" to continue the study at the site by the Investigator. Considering this, we had conducted an audit of principal investigators (PI ') compliance for Continuing Review Application (CRA) submission timelines and decision taken on the lapses in the validity of IEC approval continuation.</p><p><strong>Aim: </strong>The aim of this study is to assess the pre- and post-policy trends of non-compliance management of delayed CRA submission and compare the PI's compliance for submission of CRA between Investigator Initiated trial (IIT) and Pharma studies.</p><p><strong>Setting and design: </strong>The present study was a retrospective audit of CRAs of ongoing projects submitted by PIs to IEC, ACTREC.</p><p><strong>Materials and methods: </strong>The data from total 199 CRAs submitted for review to the IEC between the year January 2016 and December-2017 were collected and maintained in Microsoft Excel sheet, and later, the data were exported into the SPSS software version 21 for the analysis.</p><p><strong>Statistical analysis: </strong>All categorical data were presented in numbers and percentage. The first primary objective was assessed by calculating the duration between the dates of approval for any study to the date of next CRA submission. The CRAs submitted after the project expiry date were considered as a lapse in following the IEC SOP.</p><p><strong>Results: </strong>This retrospective audit revealed that CRA reminder sent by the IEC to the PI played an important role in compliance w. r. t timely in following the IEC SOPof the CRA by the PI. As a result, overall, 90% of CRAs showed compliance in submitting CRAs to IEC in both IIT and Pharma study. The number of lapses were reduced to 7 in the postpolicy period as compared to 15 lapses in the prepolicy period.</p><p><strong>Conclusion: </strong>This retrospective audit reveals that CRA reminder sent by the IEC to the PI played an important role in improving the compliance of PIs in submitting CRA to IEC. Each IEC should develop the policy to minimize the delays in CRA submission by the PI and prevent lapses in following the IEC SOP.</p>","PeriodicalId":20015,"journal":{"name":"Perspectives in Clinical Research","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/29/dc/PCR-13-145.PMC9345251.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Perspectives in Clinical Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/picr.PICR_102_20","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/2/8 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Context: A failure to obtain continued Institutional Ethics Committee (IEC) approval for the study before the expiry date assigned by the IEC is considered as "lapse of the IEC approval" to continue the study at the site by the Investigator. Considering this, we had conducted an audit of principal investigators (PI ') compliance for Continuing Review Application (CRA) submission timelines and decision taken on the lapses in the validity of IEC approval continuation.

Aim: The aim of this study is to assess the pre- and post-policy trends of non-compliance management of delayed CRA submission and compare the PI's compliance for submission of CRA between Investigator Initiated trial (IIT) and Pharma studies.

Setting and design: The present study was a retrospective audit of CRAs of ongoing projects submitted by PIs to IEC, ACTREC.

Materials and methods: The data from total 199 CRAs submitted for review to the IEC between the year January 2016 and December-2017 were collected and maintained in Microsoft Excel sheet, and later, the data were exported into the SPSS software version 21 for the analysis.

Statistical analysis: All categorical data were presented in numbers and percentage. The first primary objective was assessed by calculating the duration between the dates of approval for any study to the date of next CRA submission. The CRAs submitted after the project expiry date were considered as a lapse in following the IEC SOP.

Results: This retrospective audit revealed that CRA reminder sent by the IEC to the PI played an important role in compliance w. r. t timely in following the IEC SOPof the CRA by the PI. As a result, overall, 90% of CRAs showed compliance in submitting CRAs to IEC in both IIT and Pharma study. The number of lapses were reduced to 7 in the postpolicy period as compared to 15 lapses in the prepolicy period.

Conclusion: This retrospective audit reveals that CRA reminder sent by the IEC to the PI played an important role in improving the compliance of PIs in submitting CRA to IEC. Each IEC should develop the policy to minimize the delays in CRA submission by the PI and prevent lapses in following the IEC SOP.

Abstract Image

Abstract Image

Abstract Image

在Navi Mumbai高等肿瘤中心对主要研究者提交继续审查申请的合规性进行审计,并对机构伦理委员会批准的有效性失误作出决定。
背景:在IEC指定的截止日期之前,未能获得机构伦理委员会(IEC)对研究的持续批准,被研究者视为“IEC批准失效”,可以继续在现场进行研究。考虑到这一点,我们对持续审查申请(CRA)提交时间表的主要研究人员(PI)合规性进行了审计,并对IEC批准延续有效期的失误做出了决定。目的:本研究的目的是评估延迟CRA提交的政策前和政策后的不合规管理趋势,并比较研究者发起的试验(IIT)和制药研究之间PI对CRA提交的依从性。设置和设计:本研究是对项目管理机构向IEC、ACTREC提交的正在进行的项目的评价评估进行回顾性审计。材料与方法:将2016年1月至2017年12月共提交IEC审查的199份cra数据收集并保存在Microsoft Excel表格中,然后导出到SPSS 21版软件中进行分析。统计分析:所有分类数据均以数字和百分比表示。第一个主要目标是通过计算任何研究批准日期到下一次CRA提交日期之间的持续时间来评估。在工程项目届满日期后提交的cra会被视为未能遵守IEC标准作业程序。结果:回顾性审计发现,IEC向PI发送的CRA提醒在PI及时遵守CRA的IEC sops方面发挥了重要作用。因此,总体而言,90%的cra在IIT和制药研究中都表现出向IEC提交cra的依从性。在保单后期间,失误次数减少到7次,而在保单前期间则减少到15次。结论:本次回顾性审计显示,IEC向PI发送的CRA提醒对PI向IEC提交CRA的合规性起到了重要作用。每个IEC应制定政策,以尽量减少PI提交CRA的延迟,并防止在遵循IEC SOP时出现失误。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Perspectives in Clinical Research
Perspectives in Clinical Research Medicine-Medicine (all)
CiteScore
2.90
自引率
0.00%
发文量
41
审稿时长
36 weeks
期刊介绍: This peer review quarterly journal is positioned to build a learning clinical research community in India. This scientific journal will have a broad coverage of topics across clinical research disciplines including clinical research methodology, research ethics, clinical data management, training, data management, biostatistics, regulatory and will include original articles, reviews, news and views, perspectives, and other interesting sections. PICR will offer all clinical research stakeholders in India – academicians, ethics committees, regulators, and industry professionals -a forum for exchange of ideas, information and opinions.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信